Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
06 Julho 2023 - 5:05PM
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the
promotion of Yajing Chen to Chief Financial Officer (CFO),
effective July 7, 2023. Dr. Chen, currently Zai Lab’s Deputy CFO
based in Cambridge, MA, has been supporting the Company’s finance
function since joining in September 2021. She is a seasoned finance
executive with more than 20 years of experience in the life
sciences industry as well as a Ph.D. trained scientist. She
succeeds Billy Cho, who will be stepping down from his role and
will be pursuing a significant opportunity in private equity.
“On behalf of everyone at Zai Lab, I would like to thank Billy
for his substantial contributions and his leadership across the
organization,” said Dr. Samantha Du, Founder, Chairperson and Chief
Executive Officer of Zai Lab. “Billy helped build a solid financial
foundation for the Company and was instrumental in the development
of Zai Lab into a fully integrated biotech company. I would also
like to congratulate Yajing on her well-deserved promotion. Her
scientific background, combined with her significant executive
management experience, finance expertise at leading global
companies, and business acumen, has allowed her to bring a unique
perspective to Zai Lab. I am confident she will continue to be a
significant asset to our senior management and finance teams.”
“I am very excited to welcome Yajing into her new role as CFO,”
said Josh Smiley, President and Chief Operating Officer of Zai Lab.
“Zai Lab has had great success over the past few years and is now
entering its next phase of growth. Yajing’s deep financial
expertise and track record of achievement will help drive Zai Lab’s
future growth. I want to thank Billy for all of his contributions
to the Company over the past five years and wish him much continued
success.”
“I am excited to step into the CFO role and to lead the talented
group of individuals within the financial organization as we
execute our growth strategy,” said Dr. Chen. “I look forward to
helping guide Zai Lab as we continue to advance our mission to
transform patient lives.”
Dr. Chen has served as the Company’s Senior Vice President and
Deputy Chief Financial Officer since September 2021, helping to
oversee finance, planning and forecasting, accounting, tax,
treasury, and procurement matters. She joined the Company from
AstraZeneca where she held various roles of increasing
responsibility from 2006 to 2021, including Chief Financial Officer
for the U.S. Oncology Business Unit from 2019 to 2021 and Finance
Controller of the Global Oncology Business Unit from 2016 to 2019.
Dr. Chen earned a Ph.D. in Microbiology from New York University
and an MBA from Columbia University.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative,
research-based, commercial-stage biopharmaceutical company based in
China and the United States. We are focused on discovering,
developing, and commercializing innovative products that address
medical conditions with significant unmet needs in the areas of
oncology, autoimmune disorders, infectious diseases, and
neuroscience. Our goal is to leverage our competencies and
resources to positively impact human health in China and
worldwide.
For additional information about Zai Lab, including our
products, business activities and partnerships, research, and other
events or developments, please visit www.zailaboratory.com or
follow us at www.twitter.com/ZaiLab_Global.
Zai Lab Forward-Looking Statements
This press release contains forward-looking statements about
future expectations, plans, and prospects, including, without
limitation, statements relating to the prospects and plans for Zai
Lab’s management, operations, and growth potential. All statements,
other than statements of historical fact, included in this press
release are forward-looking statements, and can be identified by
words such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would,” and other similar expressions. Such
statements constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are not guarantees or assurances of
future performance. Forward-looking statements are based on our
expectations and assumptions as of the date of this press release
and are subject to inherent uncertainties, risks, and changes in
circumstances that may differ materially from those contemplated by
the forward-looking statements. We may not actually achieve the
plans, carry out the intentions, or meet the expectations or
projections disclosed in our forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results may differ materially from those
indicated by forward-looking statements as a result of various
important factors, including but not limited to (1) our ability to
successfully commercialize and generate revenue from our approved
products, (2) our ability to obtain funding for our operations and
business initiatives, (3) the results of our clinical and
pre-clinical development of our product candidates, (4) the content
and timing of decisions made by the relevant regulatory authorities
regarding regulatory approvals of our product candidates, (5) the
effects of the novel coronavirus (COVID-19) pandemic on our
business and results of operations, (6) risks related to doing
business in China, and (7) other factors identified in our
most recent annual and quarterly reports and in other reports we
have filed with the U.S. Securities and Exchange Commission
(SEC). We anticipate that subsequent events and developments will
cause our expectations and assumptions to change, and we undertake
no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise, except as may be required by law. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this press release.
Our SEC filings can be found on our website
at www.zailaboratory.com and on the SEC’s website
at www.sec.gov.
For more information, please contact:
Investor Relations:Christine Chiou / Lina
Zhang+1 (917) 886-6929 / +86 136 8257
6943christine.chiou1@zailaboratory.com /
lina.zhang@zailaboratory.com
Media:Shaun Maccoun / Xiaoyu Chen+1 (415)
317-7255 / +86 185 0015 5011shaun.maccoun@zailaboratory.com /
xiaoyu.chen@zailaboratory.com
Zai Lab (NASDAQ:ZLAB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Zai Lab (NASDAQ:ZLAB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024